EXPAREL (bupivacaine liposome injectable suspension) is indicated in patients 6 years of age and older for single-dose infiltration to produce postsurgical local analgesia, and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with multivesicular liposomes, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated.
| Website | http://www.exparel.com |
| Revenue | $6.5 million |
| Employees | View employees |
| Address | 5 Sylvan Way Ste 300, Parsippany, New Jersey 07054, US |
| Phone | +1 973-254-3560 |
| Industry | Hospitals & Clinics, Healthcare |
| Competitors | AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals., Endo International plc, Purdue Pharma L.P., Pacira BioSciences, Inc., Sientra, Inc., Keryx Biopharmaceuticals, Viela Bio +31 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Exparel employee's phone or email?
Exparel Questions
The Exparel annual revenue was $6.5 million in 2026.
Exparel is based in Parsippany, New Jersey.
The NAICS codes for Exparel are [3254, 325, 32, 32541].
The SIC codes for Exparel are [28, 283].
